Bavarian Nordic A/S, of Kvistgard, Denmark, reported preliminary results from a phase I study of the Ebola prime-boost vaccine regimen using the company's MVA-BN Filo vaccine plus the Advac vaccine from the Janssen Pharmaceutical unit of New Brunswick, N.J.-based Johnson & Johnson at the FDA's Vaccines and Related Biological Products Advisory Committee meeting.